What is Climb Bio, Inc.'s stock issuance proceeds?

Climb Bio, Inc. (CLYM) reported stock issuance proceeds of $5K in Q1 2026.

What is the long-term trend for Climb Bio, Inc.'s stock issuance proceeds?

Over 4 years (2021 to 2025), Climb Bio, Inc.'s stock issuance proceeds has grown at a -18.7% compound annual growth rate (CAGR), from $149K to $65K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Climb Bio, Inc. CLYM Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Vera TherapeuticsVERA

$3.94M+157%

Kyverna Therapeutics, Inc.KYTX

$243K+8,000%

Cullinan Therapeutics, Inc.CGEM

$0-100%

Jade Biosciences, Inc. Common StockJBIO

$45K+105%

Shattuck Labs, Inc.STTK

$20.56M—

Artiva Biotherapeutics, Inc.ARTV

-$138K—

Other financials

Income statement

See full

Operating income-$15.2M+33.9%

Net income-$13.7M+34.0%

EPS (diluted)-$0.20+35.5%

Balance sheet

See full

Cash & equivalents$8.4M-71.2%

Total debt$479.0K+1.1%

Total equity$148.1M-23.4%

Total assets$152.4M-24.1%

Cash flow

See full

Operating cash flow-$14.4M+6.8%

CapEx$109.0K—

Free cash flow-$15.6M-183%

Valuation

See full

Market cap$724.95M+787%

Enterprise value$717.07M+1,247%

Returns & leverage

See full

Return on equity-30.9%-10.3pp

Debt / equity0×0.0×

Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Climb Bio, Inc.'s stock issuance proceeds?: Climb Bio, Inc. (CLYM) reported stock issuance proceeds of $5K in Q1 2026.
What is the long-term trend for Climb Bio, Inc.'s stock issuance proceeds?: Over 4 years (2021 to 2025), Climb Bio, Inc.'s stock issuance proceeds has grown at a -18.7% compound annual growth rate (CAGR), from $149K to $65K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.